Valuation: BICO Group AB

Market Cap 1.54B 153M 136M 127M 116M 219M 14.78B 222M 597M 7.52B 576M 564M 24.17B P/E 2026 *
-6.79x
P/E 2027 * -12.2x
Enterprise Value 1.47B 147M 130M 122M 111M 209M 14.11B 212M 570M 7.19B 550M 538M 23.09B EV / Sales 2026 *
0.91x
EV / Sales 2027 * 0.82x
Free-Float
69.88%
Yield 2026 *
-
Yield 2027 * -
1 day-4.80%
1 month+3.86%
3 months+22.02%
6 months+5.91%
Current year-12.60%
1 month 2.15
Extreme 2.15
2.26
Current year 1.52
Extreme 1.522
2.31
1 year 1.52
Extreme 1.522
2.73
3 years 1.52
Extreme 1.522
6.9
5 years 1.52
Extreme 1.522
60.45
10 years 0
Extreme 0
100
Manager TitleAgeSince
Chief Executive Officer 51 01/09/2026
Director of Finance/CFO 56 01/03/2026
Chief Operating Officer - 07/01/2026
Director TitleAgeSince
Director/Board Member 71 18/12/2019
Director/Board Member 37 01/03/2015
Director/Board Member - 07/05/2026
Change 5-day change 1-year change 3-year change Capi.($)
-4.80%-.--% - - 154M
-2.66%-2.59%+24.52%+33.29% 250B
-3.74%-4.08%+0.83%+0.42% 156B
-1.27%+0.91%-7.97%+36.67% 144B
-0.89%-2.85%-54.72%-17.81% 63.26B
-1.78%-0.58%+11.70%+23.21% 49.75B
-2.76%-2.56%+21.53%+51.86% 48.58B
-0.95%+1.07%-18.77%-21.76% 47.99B
-0.31%+3.79%-2.73%+41.79% 46.22B
-2.42%+0.13%+34.73%+59.27% 43.17B
Average -2.16%+2.27%+1.01%+22.99% 94.22B
Weighted average by Cap. -2.20%+2.37%+4.41%+23.16%

Financials

2026 *2027 *
Net sales 1.62B 161M 143M 134M 122M 230M 15.54B 233M 628M 7.91B 606M 593M 25.42B 1.69B 168M 149M 139M 127M 239M 16.15B 242M 652M 8.22B 630M 616M 26.42B
Net income -227M -22.59M -20.06M -18.76M -17.1M -32.19M -2.18B -32.63M -87.87M -1.11B -84.82M -82.98M -3.56B -126M -12.54M -11.14M -10.42M -9.49M -17.87M -1.21B -18.11M -48.78M -615M -47.08M -46.06M -1.97B
Net Debt -69M -6.87M -6.1M -5.7M -5.2M -9.79M -661M -9.92M -26.71M -337M -25.78M -25.22M -1.08B -166M -16.52M -14.67M -13.72M -12.5M -23.54M -1.59B -23.86M -64.26M -810M -62.02M -60.68M -2.6B
Logo BICO Group AB
BICO Group AB, previously Cellink AB is a Sweden-based company, which is primarily involved in the healthcare industry. The Company focuses on the application areas of bioprinting, multiomics, cell line development, and diagnostics. The Company develops and markets technologies that enable researchers in the life sciences to culture cells in 3D, perform high-throughput drug screening and print human tissues and organs for the medical, pharmaceutical, and cosmetic industries. The Company’s operations divided in two segments: The Industrial Solutions segment that offers products within precision dispensing and biosensor technology for industrial customers, which make a high-capacity contribution to customers production; and The Laboratory Solutions segment that offers 3Dprinters, single- cell and liquid- dispensing instruments as well as services and consumables related to these products.
Employees
554
Date Price Change Volume
Trader
Investor
Global
Quality
ESG MSCI
-
Sell
Consensus
Buy
Mean consensus
HOLD
Number of Analysts
1
Last Close Price
21.85SEK
Average target price
29.00SEK
Spread / Average Target
+32.72%

Quarterly revenue - Rate of surprise